6:12 PM
 | 
Dec 10, 2012
 |  BC Extra  |  Clinical News

AOP Orphan reports Phase II polycythemia vera data

AOP Orphan Pharmaceuticals AG (Vienna, Austria) reported data from 11 evaluable patients in the Phase II portion of the Phase I/II PEGINVERA trial of its subcutaneous AOP2014 to treat polycythemia...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >